Press Release
Media Contacts:
IB Communications
likarda@ibcomms.agency

Likarda Launches "Predictive Polymer Analytics™" — a Breakthrough AI Platform Revolutionizing Complex Therapy Formulation and Encapsulation

- **PPA leverages Likarda's comprehensive proprietary data to dramatically reduce formulation timelines and costs**
- **The platform has been designed with confidentiality in mind, ensuring data remains private and is not used to train public models**

Kansas City, MO – October 1, 2025 – Likarda, a global leader in complex therapy formulation for cell and large-molecule therapeutics, today announced the launch of **Predictive Polymer Analytics (PPA)™**, its next-generation artificial intelligence (AI) platform designed to radically accelerate and de-risk the formulation design process for clients developing advanced therapeutics.

For years, Likarda has been building one of the most comprehensive private data libraries of polymer performance, encapsulation chemistries, and crosslinking strategies — spanning thousands of use cases from peptides and biologics to exosomes and living cells. Now, with the rise of advanced transformer-based machine learning models, Likarda can unlock the full value of this proprietary data, guiding formulation decisions with unprecedented speed and accuracy.

Leveraging secure, RAG-based (retrieval-augmented generation) AI pipelines, the platform analyzes Likarda's terabytes of historical data and recommends the most promising polymer backbones and crosslinking approaches — reducing the number of wet-lab iterations required and significantly lowering costs for clients. Traditionally, drug developers spent weeks or months running multiple experimental iterations to identify the optimal formulation conditions that maximize viability, stability, and bioavailability. With Likarda's PPA™ platform, those timelines can be compressed dramatically.

"*This is a major leap forward for the field of drug delivery*," said Dr. Stella Vnook, CEO of Likarda. *"Our clients are developing some of the most complex therapies in the world, and speed to clinic can make or break a program. By fusing our deep scientific know-how with a purpose-built AI engine, we are turning years of accumulated formulation insights into actionable intelligence — helping clients reach optimized formulations faster, with fewer experiments, and greater confidence. This isn't AI for AI's sake — it's a direct accelerator for innovation in cell, gene, and advanced biologic therapy."*

Likarda partnered with Embedded Engineering ApS to develop the secure infrastructure underpinning PPA™, ensuring that all embeddings and retrievals are performed using Claude-based models under strict confidentiality agreements. This guarantees that client data remains private and is never used to train public models.

Likarda will be attending a Meeting on the Mesa, October 6-8, 2025, where attendees can learn how AI-driven formulation design is transforming the path from discovery to clinic.

Key Benefits of Likarda's PPA™

- **Accelerated Formulation Design** – From months to weeks with fewer wet-lab iterations
- **Cost Efficiency** – Significant reduction in experimental overhead
- **Data-Driven Decisions** – Terabytes of curated internal data powering predictive recommendations
- **Privacy & Security First** – Client IP safeguarded with enterprise-grade protections

About Likarda

Likarda is a leading biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics. These advancements aim to enhance therapeutic efficacy and offer patients a sustainable solution for their chronic or life-threatening diseases. At the heart of Likarda's innovation is the Core-Shell Spherification (CSS) technology. This revolutionary approach coats cells and biologics with inert hydrogels, ensuring they remain at their intended target location within the body and are shielded from potential degradation. This customizable platform is pivotal in maintaining cell viability and optimizing the delivery of biologics. For more insights, visit Likarda.com.